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Factors associated with concurrent illicit use of opiates and crack/cocaine among opiate-users in 
Treatment: Implications for treatment services in England.   
 
Abstract: 
 
Background: The aim of this study was to identify factors associated with concurrent illicit drug use of opiates 
and crack/cocaine use among individuals receiving of opioid medication-assisted treatment (MAT) in one English 
rural/urban County Council area.  
Methods: 776 opiate users in treatment were assessed using the Addiction Dimensions for Assessment and 
Personalised Treatment (ADAPT) assessment tool (Marsden et al, 2014). The tool encompasses three domains 
and 14 subdomains covering addiction severity, recovery strengths and coexisting health and social needs. Data 
were opportunistically matched to the National Drug Treatment Monitoring System (NDTMS) and the Treatment 
Outcome Profile (TOP). Two backward stepwise logistic regression models were run to discern the nature of 
concurrent illicit drug use.  
Results: Addiction severity (Odds Ratio [OR] 12.55, Confidence interval [CI] 6.49-24.27), low recovery strengths 
(OR 2.30, CI 1.30-4.07) and no ‘urge/control’ (OR 27.45, 13.18-57.16) were strongly associated with concurrent 
use. Individuals with moderate psychological needs were more likely to be abstinent (OR 2.97, CI 1.67-5.29) 
compared to those with no need. Abstaining from injecting (OR 2.38, CI 1.15-4.93), alcohol consumption (OR 
1.55, CI 1.05-2.30), increasing age (OR 1.03, CI 1.01-1.06) and increased quality-of-life (OR 1.05, CI 1.00-1.10) 
were associated with abstinence from concurrent use. 
Conclusion:  Practitioner assessments with self-report data offer unique perspectives on service users’ holistic 
needs. Interventions addressing concurrent use during MAT should consider managing urges and control of illicit 
Class A use, injecting and alcohol consumption within a stepped-care approach. Packages for developing recovery 
strengths supporting psychological need and enhancing quality-of-life is recommended.  
 
Keywords 
Treatment, Abstinence, Concurrent drug use 
 
 
 
2 
 
 
Submission to Addiction, Research and Theory Journal.  
5,915 words including four tables and references.  
 
Authors: 
 
Arun Sondhi (Therapeutic Solutions Addictions)* 
Lucy Pointon (Sheffield Hallam University) 
Anna Kawalek (Sheffield Hallam University) 
Allesandro Leidi (University of Reading) 
Professor David Best (Sheffield Hallam University) 
 
*corresponding author: 
Arun Sondhi  
4 Old Park Lane, London W1K 1QW  
arun.sondhi@therapeutic-solutions.org.uk 
Tel: 0800 044 3868 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
1. Introduction 
 
Chronic drug use will often lead to problematic health conditions (Stein, 1990) alongside social consequences 
such as financial difficulties, unemployment, homelessness, criminality, the breakdown of families or friendships 
or comorbid mental health problems (Hammersley et al, 2007; Craig & Hodson, 2000; Reid & Klee, 1999). Studies 
have consistently shown that problematic heroin and crack or cocaine misusing individuals make significant 
improvements in curtailing illicit drug use and criminality following treatment (Jones et al, 2009; Gossop et al, 
2003; Anglin et al, 1997; Hubbard et al, 1997; Simpson, 1990). Improvements to physical and psychological 
health have also been noted (Teeson et al, 2008; Gossop et al, 2002).  
 
The importance of identifying factors that promote reductions in illicit drug use therefore are pivotal in 
determining a positive treatment outcome. Service users who can avoid continued use of Class A substances have 
been shown to have better outcomes (Litt et al, 2003; Gossop et al, 2002) allied to length of stay in treatment 
(Jones et al, 2009; Hubbard et al, 2003; Simpson et al, 1997).  Sustained use of stimulants whilst simultaneously 
in receipt of opioid medication-assisted treatments (MAT) has been viewed as associative with unemployment 
and criminal activities (Darke et al, 2005; Hser & Anglin, 1998; Magura et al, 1998; Grella et al, 1997). 
Understanding the defining characteristics of concurrent drug use has been shown to be problematic (Beswick et 
al, 2001; Grella et al, 1997) due to changing dosage levels (Mattick et al, 2007; Best et al, 1999; Hartel et al, 
1995). Low coping efficacy has also been shown to be a predictor of continued use whilst in receipt of MAT often 
as means to manage withdrawal symptoms (Best et al, 1999; Senbanjo et al, 1999).  A meta-analysis (Brewer et 
al, 1998) identified factors associated with concurrent use of illicit substances during treatment that included the 
extent of previous episodes of abstinence relating to drug and alcohol use, the severity of drug-using prior and 
whilst in treatment, mental health factors encompassing depression and stress, unemployment, exposure to drug-
using peers and treatment factors including the extent of previous engagement with services.  
 
In the UK, treatment provision has been encouraged to become more ‘recovery-oriented’ whilst accepting a role 
for MAT (typically comprising methadone and buprenorphine) as part of a holistic package to facilitate recovery 
(National Treatment Agency, 2012). Although improvements in health-related issues and interpersonal 
relationships may occur despite continued use of substances whilst in treatment (Laudet & White, 2010; Donovan 
et al, 2005) individuals in long-term, stable recovery are more likely to report high rates of self-efficacy and are 
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able to manage a range of social problems (Hser, 2007). Services have incorporated concepts of recovery into a 
“general wellness” orientated description (Hser, 2007; Rudolf & Watts, 2002), referring to a voluntary and 
continued control over substance use, that considers housing, employment and other social needs (Laudet, 2007; 
Timpson et al, 2006). Recovery strengths can be viewed as synonymous with cross-disciplinary strengthen-based 
approaches which have been shown to establish a wide range of positive outcomes (Pattoni, 2012). Although the 
pathways to recovery are complex (Best et al, 2008), there remains a need to link appropriate interventions to an 
individual’s clinical and social needs to help promote recovery (Thornton et al, 2008) including matching 
interventions to the extent of an individual’s addiction (Timko & Sempel, 2004; McKellan et al, 1997).  
The aim of this study is to examine factors that are associated with concurrent use of illicit opiate and/or cocaine 
among a treatment population in receipt of MAT. It is hypothesized that there are factors associated with continued 
use of street opiates and cocaine that encompass complex interactions between the nature of an individual’s 
addiction and their interrelated health or social problems. Brewer et al’s (1998) list of potential factors suggest a 
range of areas for consideration including examining the extent and nature of an individual’s drug and alcohol 
use, comorbid mental health problems and social factors such as unemployment. Identification of factors 
associated with concurrent Class A drug use will aid the development of a holistic recovery-orientated response.  
 
The study reports on an opportunistic data linkage study matching an assessment of a subsample of one area’s 
MAT population’s holistic needs using a clinical assessment tool, the Addiction Dimensions for Assessment and 
Personalised Treatment (ADAPT) that has been shown to describe the wide range of clinical, social and other 
recovery-orientated issues associated with treatment engagement, with self-reported needs derived from the 
National Drug Treatment Monitoring System (NDMTS) and the Treatment Outcome Profile (TOP) to describe 
the nature of concurrent illicit opiate and cocaine use.  
 
 
2. Method 
 
2.1 Setting 
 
The study was conducted across publicly funded specialist treatment services in one mixed rural/urban County 
Council area in England. The services offered a range of clinical and psychosocial support encompassing mainly 
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methadone and buprenorphine prescribing including detoxification packages and one to one support including 
counselling, structured or peer-led group work. Treatment services adhered to a broad recovery model ensuring 
wellness and stability whilst encouraging reductions in illicit drug use.  For the purpose of this study, a subset of 
the wider treatment population was established based on whether they received MAT. There was limited 
additional information within the available datasets that allowed for a deeper analysis (for example, by dosage).  
 
2.2 Measures 
 
The Addiction Dimensions for Assessment and Personalised Treatment (ADAPT) is a validated 14-item multi-
dimensional schedule (Marsden et al, 2014) examining three domains describing ‘addiction severity’ (tolerance 
and withdrawal, urge and control, overdose risk), ‘health and social complexity’ (physical, psychological, 
personality, relationships, risk to self and others, housing, finance) and ‘recovery strengths’ (motivation, outlook 
and management, social network support, skills and participation) . The tool was chosen as a non-intrusive means 
of capturing the holistic needs of individuals in treatment to support the care-planning process at the 12-week 
point. ADAPT was selected as an appropriate tool by the treatment provider from other alternative options. The 
aim of ADAPT is to assist with the assessment and treatment planning process by matching clients to an 
appropriate intervention type (Marsden et al, 2014).  
The items were scored on a binary ‘no problem’ (0) or ‘problem identified’ (1) scale for five questions relating to 
tolerance/withdrawal, overdose risk, physical health, housing and finance needs. The remaining questions were 
scored on a four-point Likert scale reporting ‘no issue’ (0), ‘low’ (1), ‘moderate’ (2) or ‘high’ (3) needs. The 
individual scores for each component were aggregated into the three overarching domains by adding up the 
composite scores so that’ low’ need is measured between 0 and 1 for addiction severity, 0 and 2 for coexisting 
problem complexity and 0 and 5 for recovery strengths.  ‘Moderate’ needs score between 2 and 3 for addiction 
severity, 3 and 5 for coexisting problem severity and 6-8 for recovery strengths. Scores of between 4 and 5 for 
addiction severity, 6-15 for coexisting problem severity and 9 to 11 for recovery strengths indicate ‘high’ levels 
of need.  
The use of these measures was based on practitioner perceptions of need, and were originally calculated to reflect 
include age, gender, nature of illicit drug use, treatment received including length of time in treatment (Mardsen 
et al, 2014).  
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The Treatment Outcome Profile (TOP) is a self-report outcome measurement system embedded within the 
National Drug Treatment Monitoring System (NDTMS), a national (England and Wales) public health 
surveillance system. TOP gathers information about service users: current illicit drug use (prescribed medication 
is not captured); injecting behaviours (yes/no); criminal activity; a ‘health and social functioning’ component that 
encompasses psychological and physical health, housing, employment and an assessment of quality of life 
(Marsden et al, 2008).  Socio-demographic information on the treatment population were reported using NDTMS 
and levels of abstinence or concurrent drug use were captured through linking with the care-planning review 
process integrating the use of TOP. TOP is completed as part of care planning and is usually competed in 12-week 
cycles or at the point of discharge. For this study, 93% (n=719) of the TOP data were collected at 12-weeks from 
initial assessment. Concurrent opiate use therefore was calculated using TOP recoded as a dichotomous variable. 
The ADAPT assessment was applied to all clients in treatment identified as receiving MAT as of April 2017. 
Casefiles on clients were reviewed by their respective drug treatment worker. The assessment process was 
undertaken without interviewing clients directly but rather based on keyworker staff perceptions of their clients’ 
addiction-severity, health and social complexity, and recovery strengths. 
 
The combined use of self-report and a practitioner assessment provides a test for response concordance, but also 
presents a view of a service user’s holistic needs based on the strength of the client-worker relationship where a 
worker can adequately and dispassionately assess an individual’s clinical and social needs.  This increases the 
accuracy of responses and allows for an overview across a caseload by comparing service users’ needs to ensure 
consistency.  To support consistency in how workers completed ADAPT, training sessions were delivered with 
ongoing support was provided by senior management.  ADAPT data was captured on a bespoke spreadsheet and 
matched to NDTMS and TOP data using unique and anonymised client reference numbers. 
 
  
 
2.3 Statistical Analysis 
 
The subsequent analysis was undertaken on Stata v14. An initial exploration of NDTMS and TOP data was 
undertaken to check for coverage. Variables were included that met a coverage threshold of no less than 10%. 
Two questions coexisted across ADAPT, TOP and NDTMS relating to injecting status and housing needs and 
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were assessed for concordance. These related to whether a service user injected in a binary ‘yes/no’ answer, and 
an ordinal question differentiating between broad housing needs and reporting no-fixed abode. These questions 
were answered by the same practitioner and reflect their knowledge of their caseload at that point in time. These 
questions were found to have 100% percentage concordance across the three formats, which is likely to be due to 
the relative proximity between completing ADAPT and NDTMS/TOP records. It is possible that practitioners 
were influenced by knowledge of completing separate schedules with the same information, but discussions with 
the service provider suggested that practitioners provided an accurate assessment of service user’s injecting and 
housing status at these points in time.  Consequently, the ADAPT measure was utilised for data analysis. 
Following an initial exploratory phase, a binary logistic regression was used to model concurrent use of opiate 
and crack/cocaine with 14 prognostic variables available for inclusion: use of alcohol and cannabis (TOP), 
injecting (TOP), previous treatment history (NDTMS), age (NDTMS), gender (NDTMS), ethnicity (NDTMS), 
self-referral (NDTMS), criminal justice referral (NDTMS), quality of life (TOP), paid work (TOP) and three 
ADAPT domains addiction severity score rank, recovery strengths score rank and coexisting problem complexity 
score rank. 
 
A separate model was created using the same outcome variable (concurrent use versus abstinence), TOP and 
NDTMS prognostics and the 14-item subsections that comprise the three ADAPT domains to derive greater 
specificity. In this second modelling exercise, the same 14 prognostic variables were evaluated for inclusion, 
together with the 14 individual subdomains of the ADAPT framework. The two binary regression models were 
fitted to model the dichotomous outcome ‘Abstinent Opiate Crack Cocaine’. A prognostic was declared 
“statistically significant” if its p-value =< 0.05 (working at 5% significance). A backward stepwise selection 
method was used for all prognostics shown above. Seven variables were statistically associated with a change in 
the odds of not using opiates or crack cocaine whilst in treatment. 
 
 
2.4 Approvals & Ethics 
 
An application was made to the NHS Health Research Authority that stated that this study fell within the ‘service 
evaluation’ definition. Identifiable data only held by the treatment provider and this paper is based on secondary 
interrogation of anonymised data. 
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3. Results 
 
3.1 Description of the Treatment Population 
 
776 individuals were identified as in receipt of MAT as of April 2016. The characteristics of participants are 
shown in Table 1. Nearly three-quarters of the population were male (73%, n=563); with a mean age of 40.7 years 
(range 19-70 years, standard deviation 7.89) and 94% were recorded as being of white British ethnicity. Over half 
of the cohort were self-referrals (59%, n=459) with just under one-fifth (19%, n=147) referred via the criminal 
justice system.  
 
[insert Table 1 about here] 
 
Just under one-fifth (19%) of the cohort were identified by staff as having ‘high’ levels of addiction severity and 
coexisting health and social problems (Table 2). 41% were also identified as having a low level of addiction 
severity and just over half (51%) were reported as having low levels of need in relation health and social 
problems. By way of contrast 18% were shown to have ‘high’ levels of recovery strengths with 42% reported as 
at a ‘low’ level.   
 
[insert Table 2 about here] 
 
Despite receiving MAT, only 38% of the cohort were abstinent from opiate and crack/cocaine use. Just under 
three-quarters (73%, n=563) were reported as not using alcohol and 87% (n=675) were not reporting using 
cannabis at follow-up. 89% (n=687) of the cohort also reported not injecting drugs at the point of the TOP review. 
The first model (Table 3) suggested a strong relationship between continued use of opiates and crack or cocaine 
whilst in treatment and the extent of addiction severity as measured by the ADAPT tool, with a less pronounced 
relationship with concurrent illicit drug use and an individual’s recovery strengths. In comparison to a ‘high’ 
score, reporting a ‘low’ addiction severity score was associated with an Odds Ratio (OR) of 12.55, 95% 
Confidence Interval [CI]) [6.49, 24.27] suggesting that ‘low’ severity will increase the odds of abstinence by over 
12 times that of service users with ‘high’ levels of severity.   This is in comparison to individuals who will be 
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twice as likely to be abstinent if their addiction severity is ‘moderate’ compared to ‘high’ (OR 2.49; 95% [1.30, 
4.77]).   
 
There is also an association between service users with higher reported recovery strengths and not using illicit 
drugs concurrently. Individuals reporting ‘high’ levels of recovery strengths were shown to be twice as likely (OR 
2.30; 95%, [1.30, 4.07]) to report abstaining from opiate or crack/cocaine use relative to a low score. The 
relationship between not using opiate and crack/cocaine with the ADAPT domains became more nuanced when 
considering the effect of health and social coexisting problems.  Contrary to what one may expect, individuals in 
MAT with ‘moderate’ and ‘high’ coexisting health and social problems were more likely to be abstinent compared 
to individuals with no needs. Those in MAT were twice as likely to report not using opiates and crack/cocaine if 
they report ‘high’ (OR 2.20; 95% CI; 1.23, 3.92) or ‘moderate' (OR 1.91; 95% CI; 1.23, 3.92) health and social 
coexisting problems compared to a low score. 
 
Other indicators derived from TOP were associated with abstinence from use of opiate and crack/cocaine. Current 
levels of injecting predicted abstaining from opiate and crack/cocaine (OR 2.38; 95%; [1.15, 4.93]) as did 
abstaining from alcohol (OR 1.55; 95%; [1.05, 2.30]). Two additional numerical prognostics were shown to be 
associated with abstinence. Firstly, a ‘quality of life’ measure (derived from a 0-20 Likert scale using TOP) shows 
for every 1-point increase in an individual’s quality of life measure there is a 5% relative increase in the odds of 
being abstinent from use of opiate or crack/cocaine drugs (OR 1.05; 95% CI; 1.0, 1.10). Secondly, increasing age 
was also shown to be associated with no longer using opiates and crack/cocaine (OR 1.03; [1.01, 1.06]) although 
it should be noted that the effect sizes for these two prognostics were small. 
 
[insert Table 3 about here] 
 
 
A second logistic regression model (Table 4) examined associations between abstaining from opiate and crack/ 
cocaine and the 14-items subdomains (excluding the main ADAPT domains). Five variables were associated with 
a change in the odds of abstaining from using opiate and crack/cocaine. Service users with no reported ‘urge’ 
(‘urge and control’ sub-domain) to use were shown to 27 times more likely to be abstinent compared to users with 
10 
 
a ‘strong and persistent desire’ to use, although the wide confidence levels should be noted (OR 27.45; [13.18, 
57.16]).  
 
Psychological health which forms the coexisting problem complexity domain was also a significant factor. 
Perhaps counter-intuitively, individuals with ‘high’ levels of need in relation to psychological health were shown 
to be five times more likely to be abstinent compared to having ‘no’ psychological health issues (OR 5.36; [1.09, 
26.36]). Caution is advised in the interpretation of this finding due to the wide confidence level shown. Individuals 
were twice as likely (OR 2.00; [1.3, 3.1]) if they reported ‘low’ levels of need and three times as likely (OR 2.97; 
[1.67, 5.29]) to be abstinent if a service user stated ‘moderate’ needs. As with the previous model examining the 
three domains, injecting status (OR 2.58; [1.21, 5.49]), quality of life (OR 1.06, [1.02, 1.11]) and age (OR 1.03; 
[1.0, 1.1]) were also shown to be associated with abstinence from opiate and crack/cocaine use although the effect 
sizes for the latter two prognostics were relatively small.  
 
[insert Table 4 about here] 
 
4. Discussion 
 
The findings highlight the relative importance of treating addiction severity, and the ‘urge and control’ subdomain 
as a corollary to concurrent illicit opiate and crack/cocaine use which confirms previous research (Brewer et al, 
1998). The ability to control urges and cravings are often cited as a predictor of relapse (Verheual & Brink, 2005). 
The strength of this relationship may suggest the need for services to develop a carefully calibrated stepped-care 
approach, focusing on treating an individual’s immediate addiction needs supported by a package developing 
recovery strengths (Maremmani et al, 2006). The findings confirm variables associated with continued use include 
injecting status (Darke et al, 2005), ongoing drinking (Heidbrecht et al, 2018) and a relationship with quality-of-
life (Best et al, 2011a; 2011b; Donovan et al, 2005). The correlation between age and abstinence is shown in the 
wider desistance literature in that involvement in illicit activities are predicted by the ageing process (Kasemian, 
2007) encompassing life transitions and experiences (Sampson & Laub, 1993), although this has been shown to 
be moderated by ongoing opiate use (Pierce et al, 2015).   
 
11 
 
The findings confirm the importance of developing recovery strengths as means to curtailing illicit drug use, 
although the causal ordering of this effect cannot be assessed using current data. Compared to Brewer’s meta-
analysis (1998), no association was noted with unemployment which may be due to large numbers of the treatment 
population being recorded as unemployed or economically inactive.  The association between coexisting problems 
(which was driven by psychological needs as one of its subdomains) and abstinence may be considered counter 
intuitive as psychological distress has been theorised to form “negative” recovery capital (Cloud & Granfield, 
2008). Prevalence rates for psychological disorders are known to be high among those with substance use issues 
(Marsden et al, 2000) and dual diagnosis issues have been shown to result in lower acceptance and adherence to 
treatment programmes, often resulting in poorer treatment outcomes including relapse (Chung, 2005; Grella et al, 
2001; Winters, 1999; Kaminer et al, 1992).  
 
Although there is evidence that mental health disorders may precede drug use (Shivola et al, 2008), there may be 
a link between increased psychological need for those in treatment due to prior drug use causing withdrawal 
symptoms (Alaja et al, 1997) and withdrawal psychosis (Levinson et al, 1994). An Australian longitudinal cohort 
study of heroin users in treatment found abstinence was also correlated with elevated levels of psychological 
distress (Darke et al, 2007). The authors speculated that psychological distress was used a motivator for 
behavioural changes including becoming drug free.   
 
This study offers a unique opportunity to understand service users’ holistic needs (addiction severity, coexisting 
health and social problems and recovery strengths) based on a validated assessment schedule using practitioner 
perspectives of their caseload combined with self-report data. Practitioner perspectives offer objective and 
accurate assessments of an individual’s holistic needs based on the strength of the therapeutic relationship and 
allowing for comparisons to be made across a caseload. This will ensure consistency in establishing the severity 
of clinical or social needs.  There is also an opportunity to further develop and refine the findings using more 
focused tools that examine the relationship with the other prognostics shown in this study. For example, more 
work is required to understand the association between mental health issues, engagement in treatment and receipt 
of MAT with concurrent use.  
 
 
5. Strengths and Limitations 
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Few UK studies have focused on the relationship between concurrent illicit drug use and engagement in MAT. 
This study provides an overview of holistic and recovery-focused factors that are associated with concurrent use 
of opiates and crack/cocaine whilst in MAT. The large cohort size with no missing or unknown cases enhance the 
utility of the data collected.  Information collected as part of the care-planning process enhances is based on the 
strength of the worker-client relationship and offers a unique assessment into the complex nature of an individual’s 
narrative whilst in receipt of MAT.  
 
The study also has some limitations. Firstly, the study was based on a single location within one English mixed 
rural/urban County Council area rather than a multicentre study. Secondly, whilst the study demonstrates 
statistical associations between concurrent illicit drug use and a range of prognostic variables, it is limited in terms 
of its explanatory capacity, as certain key variables were not available including dose levels. Finally, ADAPT and 
NDTMS/TOP were opportunistically matched based on the treatment services’ 12-week review process rather 
than assessing measures over a longer time period (for example, at six months or beyond).  
 
6. Concluding Remarks 
 
This study highlights the extent and nature of concurrent illicit opiate and cocaine use among individuals in receipt 
of MAT. Our findings suggest there are opportunities for developing coherent and tailored responses that situate 
concurrent use within a recovery-orientated approach. Interventions aimed at addressing concurrent Class A use 
whilst in receipt of MAT therefore should consider a stepped-care approach that focuses on managing substance 
misuse (urges and control, supporting reductions in injecting and alcohol consumption) that is age-specific (e.g. 
calibrated towards younger service users). This approach should be augmented by interventions enhancing an 
individual’s recovery strengths supporting psychological needs to sustain an improved quality-of-life within an 
integrated package of care. 
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TABLES  
 
Table 1: Socio-Demographic & Treatment-referral Profile of Participants receiving MAT (n=776) 
 
Client Characteristics Number Percentage 
Gender   
- Male 563 73% 
- Female 213 27% 
Ethnic Group   
- White  719 93% 
- Non-White 57 7% 
Referral Route   
- Self 459 59% 
- Criminal Justice 147 19% 
- Other 170 22% 
 Mean Age/Range Standard Deviation 
Age 40.7 years (19-70 years) 7.89 
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Table 2: ADAPT Domain Group Strata, (n=776) 
 
 Addiction Severity Coexisting Health and Social Problems Recovery Strengths 
 Number Percentage Number Percentage Number Percentage 
Low 320 41% 394 51% 324 42% 
Moderate 311 40% 234 30% 313 40% 
High 145 19% 148 19% 139 18% 
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Table 3: Association between ADAPT and TOP measures and being abstinent from Opiate and/or 
crack/cocaine: logistic regression (n=776) 
 
 Odds 
Ratio 
P>[z] 95% Confidence Interval 
Addiction Severity Rank    
1. Low 12.55 0.000 [6.49, 24.27] 
2. Moderate 2.49 0.006 [1.30, 4.77] 
3. High 1 (base)   
Recovery Strengths Rank    
1. Low 1 (base)   
2. Moderate 1.37 0.143 [0.90, 2.10] 
3. High 2.30 0.004 [1.30, 4.07] 
Health and Social Complexity 
Rank 
   
1. Low 1 (base)   
2. Moderate 1.91 0.004 [1.23, 2.96] 
3. High 2.20 0.008 [1.23, 3.92] 
Abstain from Alcohol (TOP)    
No 1 (base)   
Yes 1.55 0.027 [1.05, 2.30] 
Abstain from Injecting (TOP)    
No 1 (base)   
Yes 2.38 0.02 [1.15, 4.93] 
Quality of Life 1.05 0.039 [1.00, 1.10] 
Age 1.03 0.004 [1.01, 1.06] 
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Table 4: Effect sizes and p-values for dichotomous outcome (14 ADAPT subdomains) 
 
 Odds 
Ratio 
P>[z] 95% Confidence Interval 
Urge and Control    
None 27.45 0.000 [13.18, 57.16] 
Low 5.61 0.000 [2.86, 11.00] 
Moderate 1.20 0.605 [0.60, 2.43] 
High 1 (base)   
Psychological Health    
None 1 (base)   
Low 2.00 0.002 [1.29, 3.10] 
Moderate 2.97 0.000 [1.67, 5.29] 
High 5.36 0.039 [1.09, 26.36] 
Abstain from Injecting (TOP)    
No 1 (base)   
Yes 2.58 0.014 [1.21, 5.49] 
Quality of Life 1.06 0.009 [1.02, 1.11] 
Age 1.03 0.026 [1.00, 1.05] 
 
 
